Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.57 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL510766 | 0.82 | ALDH1A1 (0.52) | XDHALDH1A1POLBLMNAKDM4E | |
| SCHEMBL8016483 | 0.80 | HTR6 (0.57) | FGFR1FGFR2ALDH1A1POLBALOX15 | |
| SCHEMBL508892 | 0.78 | CYP1A2 (0.48) | XDHALDH1A1LMNAGAAACMSD | |
| SCHEMBL8677237 | 0.72 | XDH (0.68) | XDHALDH1A1POLBKDM4EMAPT | |
| SCHEMBL4525328 | 0.72 | FGFR1 (0.54) | FGFR1FGFR2XDHALDH1A1POLB | |
| Bropirimine SCHEMBL509127 | 0.71 | XDH (1.00) | FGFR1FGFR2XDHALDH1A1KDM4E | |
| SCHEMBL18041785 | 0.70 | TGFBR1 (0.52) | ALDH1A1POLBLMNAKDM4EADORA3 | |
| SCHEMBL1031056 | 0.69 | FGFR1 (0.48) | FGFR1FGFR2ALDH1A1POLBALOX15 | |
| SCHEMBL14960337 | 0.67 | FGFR1 (0.55) | FGFR1FGFR2ALDH1A1POLBALOX15 | |
| SCHEMBL13539588 | 0.67 | POLB (0.47) | FGFR1FGFR2ALDH1A1POLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | FGFR1 934/4885FGFR2 1937/4885XDH 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.